GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eterna Therapeutics Inc (NAS:ERNA) » Definitions » Cash Flow from Investing
中文

Eterna Therapeutics (Eterna Therapeutics) Cash Flow from Investing : $0.00 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Eterna Therapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Dec. 2023, Eterna Therapeutics spent $0.00 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Eterna Therapeutics gained $0.00 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Dec. 2023.


Eterna Therapeutics Cash Flow from Investing Historical Data

The historical data trend for Eterna Therapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eterna Therapeutics Cash Flow from Investing Chart

Eterna Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
-0.04 -22.74 -0.05 -0.02

Eterna Therapeutics Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.13 - - - -

Eterna Therapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Eterna Therapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Eterna Therapeutics's Cash Flow from Investing for the quarter that ended in Dec. 2023 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eterna Therapeutics  (NAS:ERNA) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Eterna Therapeutics's purchase of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Eterna Therapeutics spent $0.00 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Eterna Therapeutics's sale of property, plant, equipment for the three months ended in Dec. 2023 was $0.00 Mil. It means Eterna Therapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Eterna Therapeutics's purchase of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Eterna Therapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Eterna Therapeutics's sale of business for the three months ended in Dec. 2023 was $0.00 Mil. It means Eterna Therapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Eterna Therapeutics's purchase of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Eterna Therapeutics spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Eterna Therapeutics's sale of investment for the three months ended in Dec. 2023 was $0.00 Mil. It means Eterna Therapeutics gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Eterna Therapeutics's net Intangibles purchase and sale for the three months ended in Dec. 2023 was $0.00 Mil. It means Eterna Therapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Eterna Therapeutics's cash from discontinued investing activities for the three months ended in Dec. 2023 was 0.00 Mil. It means Eterna Therapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Eterna Therapeutics's cash from other investing activities for the three months ended in Dec. 2023 was $0.00 Mil. It means Eterna Therapeutics paid $0.00 Mil for other investing activities.


Eterna Therapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Eterna Therapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Eterna Therapeutics (Eterna Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141
Eterna Therapeutics Inc is a biopharmaceutical company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.
Executives
Dorothy J Clarke director C/O ETERNA THERAPEUTICS INC., 1035 CAMBRIDGE STREET, STE. 18A, CAMBRIDGE MA 02141
Charles Cherington 10 percent owner ONE BOW STREET, CAMBRIDGE MA 02138
Brant Binder director C/O TRUST CO OF THE SWEST, 200 PARK AVE SUITE 220, NEW YORK NY 01066
Richard W Wagner director C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER ST, WALTHAM MA 02451
Curtis W Huft 10 percent owner 4510 LAMESA HWY, SNYDER TX 79549
Freebird Partners Lp 10 percent owner 2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
Freebird Investments Llc 10 percent owner 2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
John D Halpern 10 percent owner
Nicholas Jason Singer director 1395 BRICKELL AVENUE, SUITE 800, MIAMI FL 33131
William A. Wexler director 12 GILL STREET, SUITE 4650, WOBURN MA 01801
Gregory Fiore director 10355 SCIENCE CENTER DRIVE, SUITE 150, SAN DIEGO CA 92121
Andrew C. Jackson officer: Chief Financial Officer 11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130
Matthew Angel officer: Interim President and CEO 10531 4S COMMONS DRIVE, SUITE 160-550, SAN DIEGO CA 92127
Heather B Redman director TWO NORTH NINTH STREET, ALLENTOWN PA 18101
Erin S. Enright director 666 PLAINSBORO ROAD, PLAINSBORO NJ 08536

Eterna Therapeutics (Eterna Therapeutics) Headlines

From GuruFocus

Brooklyn ImmunoTherapeutics Announces Board Changes

By GuruFocusNews GuruFocusNews 06-07-2022

Eterna Therapeutics to Present at iPSC-Derived Immunotherapies Congress

By Value_Insider Value_Insider 10-18-2022

Jeff Karp, Ph.D., Joins Eterna's Scientific Advisory Board

By sperokesalga sperokesalga 03-28-2023